Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious program, conolidine modulates alternate molecular targets. A Science Improvements research identified that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid https://torreyi209uus9.wikicorrespondence.com/user